AMGN Amgen Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AMGN

Price (delayed)

$334.93

Market cap

$179.67B

P/E Ratio

47.58

Dividend/share

$8.76

EPS

$7.04

Enterprise value

$233.98B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The revenue has grown by 13% year-on-year and by 4.8% since the previous quarter
The P/E is 129% above the 5-year quarterly average of 20.7 and 95% above the last 4 quarters average of 24.3
AMGN's quick ratio has dropped by 68% year-on-year and by 15% since the previous quarter
Sector: Healthcare
Industry: Drug Manufacturers - General
Website: http://www.amgen.com/
Peers: BMY PFE GILD ABBV

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
536.43M
Market cap
$179.67B
Enterprise value
$233.98B
Valuations
Price to earnings (P/E)
47.58
Price to book (P/B)
35.74
Price to sales (P/S)
6.08
EV/EBIT
31.19
EV/EBITDA
19.38
EV/Sales
7.92
Earnings
Revenue
$29.53B
EBIT
$7.5B
EBITDA
$12.07B
Free cash flow
$7.1B
Per share
EPS
$7.04
Free cash flow per share
$13.24
Book value per share
$9.37
Revenue per share
$55.1
TBVPS
$80.29
Balance sheet
Total assets
$92.98B
Total liabilities
$87.96B
Debt
$64.02B
Equity
$5.02B
Working capital
$8.32B
Liquidity
Debt to equity
12.75
Current ratio
1.42
Quick ratio
0.84
Net debt/EBITDA
4.5
Margins
EBITDA margin
40.9%
Gross margin
66.4%
Net margin
12.7%
Operating margin
23.6%
Efficiency
Return on assets
4.1%
Return on equity
58.6%
Return on invested capital
10%
Return on capital employed
10.2%
Return on sales
25.4%
Dividend
Dividend yield
2.62%
DPS
$8.76
Payout ratio
124.4%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
0.19%
1 week
1.1%
1 month
7.07%
1 year
42.4%
YTD
16.29%
QTD
7.19%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$29.53B
Gross profit
$19.6B
Operating income
$6.97B
Net income
$3.76B
Gross margin
66.4%
Net margin
12.7%
The net margin has dropped by 58% year-on-year and by 47% since the previous quarter
The net income has plunged by 52% YoY and by 44% from the previous quarter
The company's operating margin fell by 31% YoY and by 16% QoQ
AMGN's operating income is down by 22% year-on-year and by 12% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
AMGN P/E details
P/E
47.58
P/B
35.74
P/S
6.08
EV/EBIT
31.19
EV/EBITDA
19.38
EV/Sales
7.92
The P/E is 129% above the 5-year quarterly average of 20.7 and 95% above the last 4 quarters average of 24.3
AMGN's EPS has dropped by 52% year-on-year and by 44% since the previous quarter
The stock's price to book (P/B) is 56% more than its last 4 quarters average of 22.8 and 27% more than its 5-year quarterly average of 28.0
Amgen's equity has decreased by 19% from the previous quarter and by 6% YoY
The P/S is 19% more than the last 4 quarters average of 5.1 and 17% more than the 5-year quarterly average of 5.2
The revenue has grown by 13% year-on-year and by 4.8% since the previous quarter

Efficiency

How efficient is Amgen business performance
The ROE has plunged by 72% YoY and by 43% from the previous quarter
AMGN's return on assets has dropped by 64% year-on-year and by 44% since the previous quarter
The ROIC has contracted by 48% YoY and by 31% from the previous quarter
AMGN's return on sales is down by 38% year-on-year and by 33% since the previous quarter

Dividends

What is AMGN's dividend history
Dividend details
DPS
$8.76
Dividend yield
2.62%
Payout ratio
124.4%
Recent dividends

Financial health

How did Amgen financials performed over time
Amgen's total assets is 6% more than its total liabilities
AMGN's quick ratio has dropped by 68% year-on-year and by 15% since the previous quarter
Amgen's current ratio has plunged by 55% YoY and by 14% from the previous quarter
AMGN's debt to equity is up by 23% QoQ and by 11% YoY
Amgen's equity has decreased by 19% from the previous quarter and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.